Mod­er­na takes one more step along the high-wire act of Covid-19 vac­cine work, of­fer­ing mark­ers of suc­cess for the most vul­ner­a­ble age group

One of the big ques­tions fac­ing any of the Covid-19 vac­cines is whether or not they can pro­tect the el­der­ly — the most vul­ner­a­ble group fac­ing a po­ten­tial­ly lethal virus.

We don’t know yet how that will play out in event-dri­ven Phase II­Is with 30,000 pa­tients, but Mod­er­na $MR­NA to­day just of­fered up a safe­ty and ef­fi­ca­cy pro­file for their vac­cine in an ear­ly-stage test that pro­vides some clear bio­mark­er da­ta back­ing up mR­NA-1273 across the spec­trum of age groups now un­der the mi­cro­scope. And that takes them one step clos­er to po­ten­tial­ly field­ing a new vac­cine for what could pan out as a glob­al, $20 bil­lion mar­ket.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters